Barton P. Bandy - 22 Jul 2021 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
President and CEO, Director
Signature
/s/Barton P. Bandy
Issuer symbol
RSLS
Transactions as of
22 Jul 2021
Transactions value $
-$851,088
Form type
4
Filing time
17 Sep 2021, 19:07:03
Previous filing
24 Jun 2021
Next filing
12 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Award $0 +960K $0.00 960K 22 Jul 2021 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Award $0 +226K +23.53% $0.00 1.19M 22 Jul 2021 Direct F2
transaction RSLS Common Stock, $0.001 par value per share Sale -$851K -294K -24.83% $2.89 892K 10 Sep 2021 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares will vest and be issued with respect to 480,050 shares on July 22, 2021 and the remaining shares vesting monthly thereafter for 36 months pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
F2 These shares will vest and be issued monthly over 36 months beginning on July 22, 2021 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
F3 These shares were sold to cover taxes in connection with the vesting of restricted stock units.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $2.90, inclusive. The Reporting Person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.